Evidence Hub

MP35-07 comparison of three different tadalafil regimes for the treatment of erectile dysfunction in diabetes mellitus patients with microvascular complications

Göksel Bayar, Çağlar Yıldırım

The Journal of Urology, 2022

60 participants

Abstract

You have accessJournal of UrologyCME1 May 2022MP35-07 COMPARISON OF THREE DIFFERENT TADALAFIL REGIMES FOR THE TREATMENT OF ERECTILE DYSFUNCTION IN DIABETES MELLITUS PATIENTS WITH MICROVASCULAR COMPLICATIONS Goksel Bayar and Caglar Yildirim Goksel BayarGoksel Bayar More articles by this author and Caglar YildirimCaglar Yildirim More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002589.07AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: We aimed to compare the efficacy and safety of daily, on-demand and daily plus optional tadalafil use in patients with microvascular complications due to diabetes mellitus (DM) and erectile dysfunction (ED). METHODS: Patients who came to our urology outpatient clinic with ED between May 2018 and March 2020, those with at least one microvascular complication due to DM (retinopathy, nephropathy, neuropathy or diabetic foot without macrovascular complications) were selected. Those with an international erectile function index score (IIEF-5) below 11 (severe and moderate) were included in the study. The patients were divided into three groups; the first group 5 mg tadalafil (Cialis™, Lilly, USA) daily, the second group 20 mg tadalafil (Cialis™, Lilly, USA) twice a week two hours before intercourse, and the third group 5 mg tadalafil daily and 2 hours before intercourse twice a week was formed to take an…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free